PPAR activation: a new target for the treatment of hypertension.
Hypertensive patients are at increased risk for cardiovascular complications. Inhibition of different pathophysiological mechanisms involved in hypertension and hypertension-related target organ damage may revert or prevent the progression of the pathological changes observed and reduce the occurrence of cardiovascular events. One of the new targets that may prevent or regress hypertensive vascular, renal, and perhaps brain changes in hypertension is the activation of nuclear receptors that have metabolic effects but also exert antiinflammatory action, the peroxisome proliferator activator receptor (PPAR) activators alpha and gamma. This review will discuss some of the evidence, both experimental and clinical, that suggests that activation of PPAR alpha and/or gamma in hypertension may exert beneficial cardiovascular protective effects.
Leibovitz
Eyal
E
Lady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, McGill University, Montreal, Quebec, Canada.
Schiffrin
Ernesto L
EL
D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000494:pharmacology*; D002318:Cardiovascular Diseases / Q000503:physiopathology / Q000517:prevention & control; D016503:Drug Delivery Systems; D006801:Humans; D006973:Hypertension / Q000188:drug therapy*; D047493:PPAR alpha / Q000187:drug effects* / Q000378:metabolism; D047495:PPAR gamma / Q000187:drug effects* / Q000378:metabolism
D000959:Antihypertensive Agents; D047493:PPAR alpha; D047495:PPAR gamma